The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Kisunla Uptake “as Expected” One Year after Approval, Says Lilly Japan Exec
One year after Japanese approval, Eli Lilly’s Kisunla (donanemab) is seeing uptake in line with the company’s expectations, according to Garrett Giles, executive director of the Alzheimer’s Disease Portfolio Brand Team at Lilly Japan. During an interview on September 18,…
To read the full story
Related Article
- Lilly Japan Pitching Unique Benefits of Kisunla with AD Drug Now on Market
December 2, 2024
- MHLW Issues Optimal Use Guideline for Kisunla
November 20, 2024
- Kisunla Gets Reimbursement Listing with Daily NHI Price of 8,560 Yen
November 14, 2024
- Japan Approves Lilly’s Kisunla, Eisai’s ALS Med, Gilead’s Trodelvy, and Lots More
September 25, 2024
BUSINESS
- Nxera Bags Japan, Select APAC Rights to Santhera’s DMD Therapy
January 9, 2026
- Shionogi’s Antibiotic Cefiderocol Approved in China
January 9, 2026
- Mochida’s EPA Drug Epadel S Wins Approval in China
January 9, 2026
- Keytruda Tops Japan Drug Sales Again in December, Marking 27-Month Run: Encise
January 9, 2026
- Hisamitsu to Go Private in Management Buyout Valued at 400 Billion Yen
January 8, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…